3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
Head and Neck Neoplasms
1
Fibromatosis, Gingival, 2
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
7
Pemetrexed
5
pembrolizumab
3
osimertinib
3
Erlotinib Hydrochloride
3
selpercatinib
2
pralsetinib
2
durvalumab
2
camrelizumab
2
Gemcitabine
2
Gefitinib
2
Cisplatin
2
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
ficlatuzumab
1
exemestane
1
entinostat
1
cobimetinib
1
ceralasertib
1
alectinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
AZD3759
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Respiratory Tract Diseases
×
patritumab
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts